title: [Akathisia].
abstract: The syndrome of akathisia typically consists of a subjective component, e.g. inner restlessness and an urge to move, and observable symptoms such as restless legs and inability to sit still. In most cases akathisia is caused by neuroleptics. There are several subtypes of akathisia according to the time of onset in the course of neuroleptic treatment. In clinical routine extrapyramidal motor disturbances are often underestimated or misinterpreted. As far as akathisia is concerned, differential diagnosis of restlessness or of repetitive movement patterns may be problematic. Non-compliance and impulsive behaviour are regarded as possible complications of akathisia, but systematic investigations are lacking. The pathophysiology of akathisia is not clear, but it probably differs from other pharmacologically induced motor disturbances. If warrantable, the first step in akathisia treatment is dose-reduction of the causing agent. Anticholinergic drugs, benzodiazepines, and beta-receptor blockers may be effective. Clinical assessment and survey of the patient's behaviour, e.g. during occupational therapy and group therapy is important for an early diagnosis of akathisia so that complications may be minimised.
authors.affiliation: Zentrum für Psychiatrie und Psychotherapie der Ruhr-Universität Bochum.
authors.forename: M
authors.initials: M
authors.lastname: Brüne
authors.forename: P
authors.initials: P
authors.lastname: Bräunig
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D017109:Akathisia, Drug-Induced / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001569:Benzodiazepines; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009460:Neurologic Examination / Q000187:drug effects
chemical_list: D000319:Adrenergic beta-Antagonists; D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D018680:Cholinergic Antagonists; D001569:Benzodiazepines